{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T03:47:25Z","timestamp":1794023245691,"version":"4.8.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T00:00:00Z","timestamp":1704326400000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Flemish Ministry of Economy, Sciences and Innovation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Schistosomiasis treatment entirely relies on a single drug, praziquantel, prompting research into alternative therapeutics. Here we evaluated the efficacy and safety of the antimalarial combination artesunate\u2013mefloquine for the treatment of schistosomiasis in a proof-of-concept, pragmatic, open-label, randomized controlled trial in primary schools of six villages endemic for schistosomiasis in northern Senegal. Children (6\u201314\u2009years) were eligible if <jats:italic>Schistosoma<\/jats:italic> eggs were detected by microscopy in urine and\/or stool. In total, 726 children were randomized 1:1 to praziquantel (standard care: 40\u2009mg\u2009kg<jats:sup>\u22121<\/jats:sup> single dose; <jats:italic>n<\/jats:italic>\u2009=\u2009364) or to artesunate\u2013mefloquine (antimalarial dosage: artesunate 4\u2009mg\u2009kg<jats:sup>\u22121<\/jats:sup> and mefloquine 8\u2009mg\u2009kg<jats:sup>\u22121<\/jats:sup> daily for three consecutive days; <jats:italic>n<\/jats:italic>\u2009=\u2009362). Eight children not meeting the inclusion criteria were excluded from efficacy analysis. Median age of the remaining 718 participants was 9\u2009years; 399 (55.6%) were male, and 319 (44.4%) female; 99.3% were infected with <jats:italic>Schistosoma haematobium<\/jats:italic> and 15.2% with <jats:italic>S. mansoni<\/jats:italic>. Primary outcomes were cure rate, assessed by microscopy, and frequency of drug-related adverse effects of artesunate\u2013mefloquine versus praziquantel at 4\u2009weeks after treatment. Cure rate was 59.6% (208\/349) in the artesunate\u2013mefloquine arm versus 62.1% (211\/340) in the praziquantel arm. The difference of \u22122.5% (95% confidence interval (CI) \u22129.8 to 4.8) met the predefined criteria of noninferiority (margin set at 10%). All drug-related adverse events were mild or moderate, and reported in 28\/361 children receiving artesunate\u2013mefloquine (7.8%; 95% CI 5.4 to 11.0) versus 8\/363 (2.2%; 95% CI 1.1 to 4.3) receiving praziquantel (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). Artesunate\u2013mefloquine at antimalarial dosage was moderately safe and noninferior to standard-care praziquantel for the treatment of schistosomiasis, predominantly due to <jats:italic>S. haematobium<\/jats:italic>. Multicentric trials in different populations and epidemiological settings are needed to confirm these findings. ClinicalTrials.gov identifier: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT03893097\">NCT03893097<\/jats:ext-link>.<\/jats:p>","DOI":"10.1038\/s41591-023-02719-4","type":"journal-article","created":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T11:02:08Z","timestamp":1704366128000},"page":"130-137","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Antimalarial artesunate\u2013mefloquine versus praziquantel in African children with schistosomiasis: an open-label, randomized controlled trial"],"prefix":"10.1038","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5868-7760","authenticated-orcid":false,"given":"Emmanuel","family":"Bottieau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moustapha","family":"Mbow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2227-8874","authenticated-orcid":false,"given":"Isabel","family":"Brosius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9mentine","family":"Roucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheikh Tidiane","family":"Gueye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ousmane Thiam","family":"Mbodj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babacar Thiendella","family":"Faye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annelies","family":"De Hondt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Smekens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Arango","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Burm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achilleas","family":"Tsoumanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Paredis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6072-4065","authenticated-orcid":false,"given":"Yven","family":"Van Herrewege","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7394-7033","authenticated-orcid":false,"given":"Idzi","family":"Potters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Rosanas-Urgell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Badara","family":"Ciss\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souleymane","family":"Mboup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Polman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,4]]},"reference":[{"key":"2719_CR1","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/S0140-6736(17)32154-2","volume":"390","author":"AA Abajobir","year":"2017","unstructured":"Abajobir, A. A. et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 390, 1211\u20131259 (2017).","journal-title":"Lancet"},{"key":"2719_CR2","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1016\/S0140-6736(13)61949-2","volume":"383","author":"DG Colley","year":"2014","unstructured":"Colley, D. G., Bustinduy, A. L., Secor, W. E. & King, C. H. Human schistosomiasis. Lancet 383, 2253\u20132264 (2014).","journal-title":"Lancet"},{"key":"2719_CR3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41572-018-0013-8","volume":"4","author":"DP McManus","year":"2018","unstructured":"McManus, D. P. et al. Schistosomiasis. Nat. Rev. Dis. Primers 4, 13 (2018).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"2719_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40249-017-0286-2","volume":"6","author":"R Bergquist","year":"2017","unstructured":"Bergquist, R., Utzinger, J. & Keiser, J. Controlling schistosomiasis with praziquantel: how much longer without a viable alternative? Infect. Dis. Poverty 6, 1\u201310 (2017).","journal-title":"Infect. Dis. Poverty"},{"key":"2719_CR5","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/S1473-3099(15)00066-3","volume":"15","author":"Y-S Lai","year":"2015","unstructured":"Lai, Y.-S. et al. Spatial distribution of schistosomiasis and treatment needs in sub-Saharan Africa: a systematic review and geostatistical analysis. Lancet Infect. Dis. 15, 927\u2013940 (2015).","journal-title":"Lancet Infect. Dis."},{"key":"2719_CR6","doi-asserted-by":"publisher","first-page":"e327","DOI":"10.1016\/S1473-3099(22)00221-3","volume":"22","author":"NC Lo","year":"2022","unstructured":"Lo, N. C. et al. Review of 2022 WHO guidelines on the control and elimination of schistosomiasis. Lancet Infect. Dis. 22, e327\u2013e335 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"2719_CR7","doi-asserted-by":"publisher","first-page":"e3286","DOI":"10.1371\/journal.pntd.0003286","volume":"8","author":"J Zwang","year":"2014","unstructured":"Zwang, J. & Olliaro, P. L. Clinical efficacy and tolerability of praziquantel for intestinal and urinary schistosomiasis\u2014a meta-analysis of comparative and non-comparative clinical trials. PLoS Negl. Trop. Dis. 8, e3286 (2014).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"2719_CR8","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13071-016-1958-7","volume":"10","author":"J Zwang","year":"2017","unstructured":"Zwang, J. & Olliaro, P. Efficacy and safety of praziquantel 40 mg\/kg in preschool-aged and school-aged children: a meta-analysis. Parasit. Vectors 10, 47 (2017).","journal-title":"Parasit. Vectors"},{"key":"2719_CR9","unstructured":"WHO. Assessing the Efficacy of Anthelminthic Drugs against Schistosomiasis and Soil-Transmitted Helminthiasis 1\u201329 (WHO, 2013)."},{"key":"2719_CR10","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1007\/s00436-011-2670-3","volume":"109","author":"W Wu","year":"2011","unstructured":"Wu, W., Wang, W. & Huang, Y. X. New insight into praziquantel against various developmental stages of schistosomes. Parasitol. Res. 109, 1501\u20131507 (2011).","journal-title":"Parasitol. Res."},{"key":"2719_CR11","first-page":"1151","volume":"63","author":"T Crellen","year":"2016","unstructured":"Crellen, T. et al. Reduced efficacy of praziquantel against Schistosoma mansoni is associated with multiple rounds of mass drug administration. Clin. Infect. Dis. 63, 1151\u20131159 (2016).","journal-title":"Clin. Infect. Dis."},{"key":"2719_CR12","doi-asserted-by":"publisher","first-page":"e0009490","DOI":"10.1371\/journal.pntd.0009490","volume":"15","author":"JMF Gardner","year":"2021","unstructured":"Gardner, J. M. F., Mansour, N. R., Bell, A. S., Helmby, H. & Bickle, Q. The discovery of a novel series of compounds with single-dose efficacy against juvenile and adult schistosoma species. PLoS Negl. Trop. Dis. 15, e0009490 (2021).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"2719_CR13","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.phrs.2016.02.017","volume":"110","author":"MEM Saeed","year":"2016","unstructured":"Saeed, M. E. M., Krishna, S., Johannes, H., Kremsner, P. G. & Efferth, T. Antischistosomal activity of artemisinin derivatives in vivo and in patients. Pharmacol. Res. 110, 216\u2013226 (2016).","journal-title":"Pharmacol. Res."},{"key":"2719_CR14","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s12639-014-0489-4","volume":"40","author":"OM Abou-shady","year":"2016","unstructured":"Abou-shady, O. M. Therapeutic effect of mefloquine on Schistosoma mansoni in experimental infection in mice. J. Parasit. Dis. 40, 259\u2013267 (2016).","journal-title":"J. Parasit. Dis."},{"key":"2719_CR15","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/S1473-3099(10)70169-9","volume":"10","author":"J Utzinger","year":"2010","unstructured":"Utzinger, J., Tanner, M. & Keiser, J. ACTs for schistosomiasis: do they act? Lancet Infect. Dis. 10, 579\u2013581 (2010).","journal-title":"Lancet Infect. Dis."},{"key":"2719_CR16","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1086\/651682","volume":"50","author":"J Keiser","year":"2010","unstructured":"Keiser, J. et al. Efficacy and safety of mefloquine, artesunate, mefloquine\u2013artesunate, and praziquantel against Schistosoma haematobium: randomized, exploratory open-label trial. Clin. Infect. Dis. 50, 1205\u20131213 (2010).","journal-title":"Clin. Infect. Dis."},{"key":"2719_CR17","first-page":"3531","volume":"18","author":"J Keiser","year":"2012","unstructured":"Keiser, J. & Utzinger, J. Antimalarials in the treatment of schistosomiasis. Curr. Pharm. Des. 18, 3531\u20133538 (2012).","journal-title":"Curr. Pharm. Des."},{"key":"2719_CR18","doi-asserted-by":"publisher","first-page":"e45867","DOI":"10.1371\/journal.pone.0045867","volume":"7","author":"L Perez del Villar","year":"2012","unstructured":"Perez del Villar, L., Burguillo, F. J., Lo, J., Muro, A. & Pe, L. Systematic review and meta-analysis of artemisinin based therapies for the treatment and prevention of schistosomiasis. PLoS ONE 7, e45867 (2012).","journal-title":"PLoS ONE"},{"key":"2719_CR19","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1093\/cid\/cis976","volume":"56","author":"A Basra","year":"2013","unstructured":"Basra, A. et al. Efficacy of mefloquine intermittent preventive treatment in pregnancy against schistosoma haematobium infection in Gabon: a nested randomized controlled assessor-blinded clinical trial. Clin. Infect. Dis. 56, 68\u201375 (2013).","journal-title":"Clin. Infect. Dis."},{"key":"2719_CR20","doi-asserted-by":"publisher","first-page":"e2975","DOI":"10.1371\/journal.pntd.0002975","volume":"8","author":"J Keiser","year":"2014","unstructured":"Keiser, J. et al. Praziquantel, mefloquine\u2013praziquantel, and mefloquine\u2013artesunate\u2013praziquantel against Schistosoma haematobium: a randomized, exploratory, open-label trial. PLoS Negl. Trop. Dis. 8, e2975 (2014).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"2719_CR21","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/S1473-3099(16)30020-2","volume":"16","author":"SB Sirima","year":"2016","unstructured":"Sirima, S. B. et al. Comparison of artesunate\u2013mefloquine and artemether\u2013lumefantrine fixed-dose combinations for treatment of uncomplicated Plasmodium falciparum malaria in children younger than 5 years in sub-Saharan Africa: a randomised, multicentre, phase 4 trial. Lancet Infect. Dis. 16, 1123\u20131133 (2016).","journal-title":"Lancet Infect. Dis."},{"key":"2719_CR22","doi-asserted-by":"publisher","first-page":"e047147","DOI":"10.1136\/bmjopen-2020-047147","volume":"11","author":"C Roucher","year":"2021","unstructured":"Roucher, C. et al. Evaluation of artesunate\u2013mefloquine as a novel alternative treatment for schistosomiasis in African children (SchistoSAM): protocol of a proof-of-concept, open-label, two-arm, individually-randomised controlled trial. BMJ Open 11, e047147 (2021).","journal-title":"BMJ Open"},{"key":"2719_CR23","doi-asserted-by":"publisher","first-page":"e330","DOI":"10.1016\/S2542-5196(20)30129-7","volume":"4","author":"E L\u00e9ger","year":"2020","unstructured":"L\u00e9ger, E. et al. Prevalence and distribution of schistosomiasis in human, livestock, and snail populations in northern Senegal: a One Health epidemiological study of a multi-host system. Lancet Planet Health 4, e330\u2013e342 (2020).","journal-title":"Lancet Planet Health"},{"key":"2719_CR24","unstructured":"Bulletin Epid\u00e9miologique Annuel du Paludisme au S\u00e9n\u00e9gal 2021 (Programme de Contr\u00f4le du Paludisme, 2022)."},{"key":"2719_CR25","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/S1473-3099(14)71004-7","volume":"15","author":"DA Karagiannis-Voules","year":"2015","unstructured":"Karagiannis-Voules, D. A. et al. Spatial and temporal distribution of soil-transmitted helminth infection in sub-Saharan Africa: a systematic review and geostatistical meta-analysis. Lancet Infect. Dis. 15, 74\u201384 (2015).","journal-title":"Lancet Infect. Dis."},{"key":"2719_CR26","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.1016\/S2214-109X(20)30398-3","volume":"9","author":"B Sartorius","year":"2021","unstructured":"Sartorius, B. et al. Prevalence and intensity of soil-transmitted helminth infections of children in sub-Saharan Africa, 2000\u201318: a geospatial analysis. Lancet Glob. Health 9, e52\u2013e60 (2021).","journal-title":"Lancet Glob. Health"},{"key":"2719_CR27","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1186\/1756-3305-4-201","volume":"4","author":"R Liu","year":"2011","unstructured":"Liu, R., Dong, H., Guo, Y., Zhao, Q. & Jiang, M. Efficacy of praziquantel and artemisinin derivatives for the treatment and prevention of human schistosomiasis: a systematic review and. Parasit. Vectors 4, 201 (2011).","journal-title":"Parasit. Vectors"},{"key":"2719_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-10-292","volume":"10","author":"P Schlagenhauf","year":"2011","unstructured":"Schlagenhauf, P. et al. Use of mefloquine in children\u2014a review of dosage, pharmacokinetics and tolerability data. Malar. J. 10, 292 (2011).","journal-title":"Malar. J."},{"key":"2719_CR29","first-page":"1","volume":"12","author":"SJ Lee","year":"2017","unstructured":"Lee, S. J., Ter Kuile, F. O., Price, R. N., Luxemburger, C. & Nosten, F. Adverse effects of mefloquine for the treatment of uncomplicated malaria in Thailand: a pooled analysis of 19, 850 individual patients. PLoS ONE 12, 1\u201316 (2017).","journal-title":"PLoS ONE"},{"key":"2719_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pntd.0005193","volume":"10","author":"A Degarege","year":"2016","unstructured":"Degarege, A. et al. Plasmodium falciparum infection status among children with schistosoma in sub-Saharan Africa: a systematic review and meta-analysis. PLoS Negl. Trop. Dis. 10, 1\u201318 (2016).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"2719_CR31","unstructured":"WHO Guidelines for Malaria. 14 March 2023 (World Health Organization, 2023)"},{"key":"2719_CR32","doi-asserted-by":"publisher","first-page":"e1499","DOI":"10.1016\/S2214-109X(20)30325-9","volume":"8","author":"LM Cohee","year":"2020","unstructured":"Cohee, L. M. et al. Preventive malaria treatment among school-aged children in sub-Saharan Africa: a systematic review and meta-analyses. Lancet Glob. Health 8, e1499\u2013e1511 (2020).","journal-title":"Lancet Glob. Health"},{"key":"2719_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pmed.1002175","volume":"13","author":"B Ciss\u00e9","year":"2016","unstructured":"Ciss\u00e9, B. et al. Effectiveness of seasonal malaria chemoprevention in children under ten years of age in Senegal: a stepped-wedge cluster-randomised trial. PLoS Med. 13, 1\u201318 (2016).","journal-title":"PLoS Med."},{"key":"2719_CR34","doi-asserted-by":"publisher","first-page":"e1003727","DOI":"10.1371\/journal.pmed.1003727","volume":"18","author":"M Cairns","year":"2021","unstructured":"Cairns, M. et al. Effectiveness of seasonal malaria chemoprevention (SMC) treatments when SMC is implemented at scale: case\u2013control studies in 5 countries. PLoS Med. 18, e1003727 (2021).","journal-title":"PLoS Med."},{"key":"2719_CR35","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1056\/NEJMoa2101746","volume":"385","author":"B Balikagala","year":"2021","unstructured":"Balikagala, B. et al. Evidence of artemisinin-resistant malaria in Africa. N. Engl. J. Med. 385, 1163\u20131171 (2021).","journal-title":"N. Engl. J. Med."},{"key":"2719_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-022-04115-8","volume":"21","author":"CV Plowe","year":"2022","unstructured":"Plowe, C. V. Malaria chemoprevention and drug resistance: a review of the literature and policy implications. Malar. J. 21, 104 (2022).","journal-title":"Malar. J."},{"key":"2719_CR37","doi-asserted-by":"publisher","first-page":"e0096022","DOI":"10.1128\/spectrum.00960-22","volume":"11","author":"JH Kattenberg","year":"2023","unstructured":"Kattenberg, J. H. et al. Malaria molecular surveillance in the peruvian amazon with a novel highly multiplexed Plasmodium falciparum AmpliSeq assay. Microbiol. Spectr. 11, e0096022 (2023).","journal-title":"Microbiol. Spectr."},{"key":"2719_CR38","doi-asserted-by":"publisher","first-page":"e0003821","DOI":"10.1371\/journal.pntd.0003821","volume":"9","author":"PL Olliaro","year":"2015","unstructured":"Olliaro, P. L. et al. Toward measuring schistosoma response to praziquantel treatment with appropriate descriptors of egg excretion. PLoS Negl. Trop. Dis. 9, e0003821 (2015).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"2719_CR39","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/S0065-308X(01)48007-9","volume":"48","author":"C Hatz","year":"2001","unstructured":"Hatz, C. The use of ultrasound in schistosomiasis. Adv. Parasitol. 48, 225\u2013284 (2001).","journal-title":"Adv. Parasitol."},{"key":"2719_CR40","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1017\/S0031182009006350","volume":"136","author":"JP Webster","year":"2009","unstructured":"Webster, J. P., Koukounari, A., Lamberton, P. H. L., Stothard, J. R. & Fenwick, A. Evaluation and application of potential schistosome-associated morbidity markers within large-scale mass chemotherapy programmes. Parasitology 136, 1789\u20131799 (2009).","journal-title":"Parasitology"},{"key":"2719_CR41","doi-asserted-by":"publisher","first-page":"e1001788","DOI":"10.1371\/journal.pmed.1001788","volume":"12","author":"N Hofmann","year":"2015","unstructured":"Hofmann, N. et al. Ultra-sensitive detection of Plasmodium falciparum by amplification of multi-copy subtelomeric targets. PLoS Med. 12, e1001788 (2015).","journal-title":"PLoS Med."},{"key":"2719_CR42","doi-asserted-by":"publisher","first-page":"e4621","DOI":"10.21769\/BioProtoc.4621","volume":"13","author":"JH Kattenberg","year":"2023","unstructured":"Kattenberg, J. H. et al. Molecular surveillance of malaria using the PF AmpliSeq custom assay for plasmodium falciparum parasites from dried blood spot DNA isolates from Peru. Bio Protoc. 13, e4621 (2023).","journal-title":"Bio Protoc."},{"key":"2719_CR43","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1046\/j.1365-3156.2001.00811.x","volume":"6","author":"B Gryseels","year":"2001","unstructured":"Gryseels, B. et al. Are poor responses to praziquantel for the treatment of Schistosoma mansoni infections in Senegal due to resistance? An overview of the evidence. Trop. Med Int. Health 6, 864\u2013873 (2001).","journal-title":"Trop. Med Int. Health"},{"key":"2719_CR44","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.ijpara.2012.02.002","volume":"42","author":"L Meurs","year":"2012","unstructured":"Meurs, L. et al. Epidemiology of mixed Schistosoma mansoni and Schistosoma haematobium infections in northern Senegal. Int J. Parasitol. 42, 305\u2013311 (2012).","journal-title":"Int J. Parasitol."},{"key":"2719_CR45","doi-asserted-by":"publisher","first-page":"e2608","DOI":"10.1371\/journal.pntd.0002608","volume":"26","author":"L Meurs","year":"2013","unstructured":"Meurs, L. et al. Micro-geographical heterogeneity in Schistosoma mansoni and S. haematobium infection and morbidity in a co-endemic community in Northern Senegal. PLoS Negl. Trop. Dis. 26, e2608 (2013).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"2719_CR46","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1093\/infdis\/jis654","volume":"207","author":"M Mbow","year":"2013","unstructured":"Mbow, M. et al. T-helper 17 cells are associated with pathology in human schistosomiasis. J. Infect. Dis. 207, 186\u2013195 (2013).","journal-title":"J. Infect. Dis."},{"key":"2719_CR47","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1111\/imm.12335","volume":"143","author":"M Mbow","year":"2014","unstructured":"Mbow, M. et al. Changes in immunological profile as a function of urbanization and lifestyle. Immunology 143, 569\u2013577 (2014).","journal-title":"Immunology"},{"key":"2719_CR48","doi-asserted-by":"publisher","first-page":"e0003959","DOI":"10.1371\/journal.pntd.0003959","volume":"28","author":"L Meurs","year":"2015","unstructured":"Meurs, L. et al. Is PCR the next reference standard for the diagnosis of schistosoma in stool? A comparison with microscopy in Senegal and Kenya. PLoS Negl. Trop. Dis. 28, e0003959 (2015).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"2719_CR49","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ijpara.2017.07.010","volume":"48","author":"T Huyse","year":"2018","unstructured":"Huyse, T. et al. Evolutionary epidemiology of schistosomiasis: linking parasite genetics with disease phenotype in humans. Int. J. Parasitol. 48, 107\u2013115 (2018).","journal-title":"Int. J. Parasitol."},{"key":"2719_CR50","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/j.ijpara.2019.08.004","volume":"49","author":"NAM Boon","year":"2019","unstructured":"Boon, N. A. M. et al. No barrier breakdown between human and cattle schistosome species in the Senegal River Basin in the face of hybridisation. Int. J. Parasitol. 49, 1039\u20131048 (2019).","journal-title":"Int. J. Parasitol."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02719-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02719-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02719-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T13:07:36Z","timestamp":1705928856000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02719-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["2719"],"URL":"https:\/\/doi.org\/10.1038\/s41591-023-02719-4","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"11 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}